Eli Lilly and Company (BMV:LLY)
Mexico · Delayed Price · Currency is MXN | Market Cap | 19.32T +38.7% |
| Revenue (ttm) | 1.39T +49.6% |
| Net Income | 466.73B +93.6% |
| EPS | 520.51 +94.8% |
| Shares Out | n/a |
| PE Ratio | 41.39 |
| Forward PE | 29.79 |
| Dividend | 116.57 (0.57%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 781 |
| Open | 20,950 |
| Previous Close | 21,458 |
| Day's Range | 20,350 - 21,033 |
| 52-Week Range | 14,600 - 21,925 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct....
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
Eli Lilly's experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug Administration.
Gate Bioscience expands Lilly drug discovery deal worth more than $870 million
Gate Bioscience said on Monday it expanded a research and licensing agreement with Eli Lilly to develop treatments targeting disease-causing proteins, in a deal potentially worth more than $870 mill...
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance dosing and reduced topical treatment use in patients with moderate-to-severe atopic dermatitis Expl...
An Investor's Guide to Intangible Assets
Although not always easy to quantify, intangible assets are one of the primary sources of strong competitive advantages for businesses and a key source of economic moats. Key Takeaways Intangible asse...
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtob...
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs...
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research...
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-...
Lilly's new weight loss combo drug outperforms tirzepatide in latest trial
Eli Lilly reported positive results from a study following EloraTZP, its experimental combo weight loss drug, noting that patients lost an average of 23.3% of their body weight.
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk fo...
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 dia...
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
A drug combination studied in people with Type 2 diabetes lowered blood sugar and helped people lose more weight than with Zepbound alone.
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% co...
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as ea...
Eli Lilly and Company Slides: Investor presentation
Eli Lilly and Company has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Lilly's experimental drug cuts weight by 21% in diabetes trial
Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial.
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesi...
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compa...
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at leas...